All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 26, 2021
Home » Blogs » BioWorld MedTech Perspectives » Enough stinky greens, med-tech wants dessert!

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Orthopedics

Enough stinky greens, med-tech wants dessert!

May 15, 2014
By Amanda Pedersen
No Comments

Black_Forest_gateauChange is what the American public was promised (or some might say threatened with) during the 2008 presidential election and for better or worse, the healthcare industry worldwide has been served an extra large helping of that change over the past six years. While the medical device industry’s palate has reacted to most of that change the way a five-year-old reacts to Brussels sprouts, this year’s menu does appear to be more appetizing. In March, two competing companies filed IPO papers on the same day. TriVascular Technologies and Lombard Medical Technologies both sell devices to treat abdominal aortic aneurysms. TriVascular initially expected to raise up to $100 million in its IPO but instead the company raised $78 million in its debut on the Nasdaq Global Select Market. Lombard priced its IPO of 5 million shares at $11 a share. One expert in the medical device space and a regular contributor to Medical Device Daily, Larry Haimovitch, called this recent up-tick of device IPOs “very encouraging” and said he expects the industry to see more companies filing IPOs this year. “Finally the IPO window has opened up,” Haimovitch said. To put it into perspective, last year 30 device startups were acquired by larger companies while only four went public, according to industry tracker VentureSource. One company that nixed its IPO plans last November, citing poor market conditions, has regained its appetite for the public market. CardioDx is revisiting its plans for an IPO. The diagnostic company previously intended to offer 5 million shares at a range of $14 to $16 a piece. The industry has also been treated to a number of flavorful mergers this year. In April, Zimmer and Biomet cooked up a rather spicy deal in orthopedics. Zimmer has agreed to pay $13.35 billion in cash and stock for Biomet. The combined company stands to gain a much larger slice of the orthopedic pie. Zimmer-Biomet has been the largest M&A entrée in the orthopedic sector this year, but certainly not the first. Smith & Nephew said in February it would buy ArthroCare for $1.7 billion and there could easily be more multi-billion dollar transactions in the orthopedic space this year. Paul Teitelbaum, managing director and medical device/healthcare IT M&A expert at Mesirow Financial’s Investment Banking Group, said it would not be a surprise if Zimmer continued to add a few more acquisitions to its plate. “This isn’t the beginning of hot M&A activity in medical devices but it’s certainly not the end of it,” Teitelbaum said in reference to the Zimmer-Biomet deal. Before the year is over, the healthcare industry will likely have to choke down more change that we’ll all want to turn our nose up at. But if these recent M&As and IPOs are any indication, the sweetest dish for med-tech is yet to come. Bring on the dessert!

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing